Pradaxa (Dabigatran) Approved as Alternative to Warfarin for Reducing Atrial Fibrillation Stroke Risk

Rate This

The long-awaited alternative to Coumadin (warfarin) has just been approved by the United States Food and Drug Administration. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation (afib) for preventing afib-related strokes.

The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa doesn't require the monitoring nor the restrictive diet that warfarin does.

Learn more at:
FDA Approves Pradaxa as Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation

Mellanie True Hills Bio

Atrial Fibrillation: Symptoms, Causes and Risks

6 Reasons You May Be Getting Heart Palpitations

MRI May Help Determine Stroke Risk for Those With Afib Some Day

New Five Box Maze Procedure Is Promising Treatment for Persistent Atrial ...

Add a Comment1 Comments

Anonymous

I took one150mg tablet per day for a month w/o any adverse reactions. I now have a prescription based on that and want to continue that same dosage but the manufacturers recommended dosage is 2 tablets per day. As a patient with two previous periods of Atrial Fib, will I not be relatively safe from clotting compared to the last seven years with just Plavix and baby aspirin. I am taking 2 tablets of Sotalol per day and wish to avoid further side affects.

February 8, 2011 - 11:21pm

This Comment

Improved My Health
Changed My Life
Saved My Life

Add a Comment

Mellanie True Hills Expert View Profile Send Message

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.